Intech Investment Management LLC Increases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Intech Investment Management LLC raised its stake in DexCom, Inc. (NASDAQ:DXCM) by 2,083.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 387,330 shares of the medical device company’s stock after purchasing an additional 369,587 shares during the quarter. Intech Investment Management LLC owned 0.10% of DexCom worth $25,967,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Capital Insight Partners LLC grew its position in DexCom by 2.5% during the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after acquiring an additional 90 shares during the period. HM Payson & Co. grew its position in DexCom by 6.0% during the first quarter. HM Payson & Co. now owns 1,780 shares of the medical device company’s stock valued at $247,000 after acquiring an additional 100 shares during the period. Clear Creek Financial Management LLC boosted its position in shares of DexCom by 4.2% in the second quarter. Clear Creek Financial Management LLC now owns 2,961 shares of the medical device company’s stock worth $336,000 after buying an additional 120 shares during the period. SeaCrest Wealth Management LLC boosted its position in shares of DexCom by 3.6% in the second quarter. SeaCrest Wealth Management LLC now owns 4,421 shares of the medical device company’s stock worth $501,000 after buying an additional 152 shares during the period. Finally, Securian Asset Management Inc. boosted its position in shares of DexCom by 0.7% in the second quarter. Securian Asset Management Inc. now owns 22,866 shares of the medical device company’s stock worth $2,593,000 after buying an additional 161 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares in the company, valued at $18,318,872.25. This trade represents a 0.28 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

DexCom Stock Up 0.5 %

Shares of DexCom stock opened at $75.24 on Thursday. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The business’s 50 day simple moving average is $70.29 and its 200-day simple moving average is $90.44. The stock has a market capitalization of $29.39 billion, a price-to-earnings ratio of 45.05, a PEG ratio of 2.30 and a beta of 1.17. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Sanford C. Bernstein upped their target price on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research report on Friday, October 25th. Robert W. Baird upped their target price on DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research report on Monday, August 5th. Piper Sandler reaffirmed an “overweight” rating and issued a $90.00 target price on shares of DexCom in a research report on Monday, August 26th. Raymond James reduced their price target on DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Finally, UBS Group reduced their price target on DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a report on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.